Compare UFPT & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UFPT | MESO |
|---|---|---|
| Founded | 1963 | 2004 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 1996 | 2005 |
| Metric | UFPT | MESO |
|---|---|---|
| Price | $295.98 | $14.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $355.00 | $37.00 |
| AVG Volume (30 Days) | 74.7K | ★ 152.2K |
| Earning Date | 11-02-2026 | 08-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.44 | N/A |
| EPS | ★ 4.92 | N/A |
| Revenue | ★ $602,797,000.00 | N/A |
| Revenue This Year | $9.23 | $58.89 |
| Revenue Next Year | $5.41 | $58.93 |
| P/E Ratio | $59.98 | ★ N/A |
| Revenue Growth | ★ 19.50 | N/A |
| 52 Week Low | $173.86 | $13.05 |
| 52 Week High | $338.71 | $21.50 |
| Indicator | UFPT | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 55.64 | 40.06 |
| Support Level | $224.12 | $14.18 |
| Resistance Level | $330.51 | $16.06 |
| Average True Range (ATR) | 7.18 | 0.40 |
| MACD | 1.79 | -0.08 |
| Stochastic Oscillator | 77.98 | 9.78 |
UFP Technologies Inc is a contract development and manufacturing organization that specializes in single-use and single-patient medical devices. The company manufactures its products by converting raw materials using laminating, molding, radio frequency, and impulse welding, and fabricating manufacturing techniques. It is an important link in the medical device supply chain and a valued outsource partner to many of the top medical device manufacturers in the world. The company's single-use and single-patient devices and components are used in a wide range of medical devices, disposable wound care products, infection prevention, minimally invasive surgery, wearables, orthopedic soft goods, and orthopedic implant packaging.
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.